CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer
✍ Scribed by Mauro Antonio Alves Castro; Felipe Dal-Pizzol; Stephanie Zdanov; Marcio Soares; Carolina Beatriz Müller; Fernanda Martins Lopes; Alfeu Zanotto-Filho; Marilda da Cruz Fernandes; Jose Claudio Fonseca Moreira; Emily Shacter; Fábio Klamt
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 708 KB
- Volume
- 116
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND Methylation of CpG islands in the promoter and upstream coding regions has been identified as a mechanism for transcriptional inactivation of tumor suppressor genes. The purpose of the current study was to determine the correlation between the aberrant promoter methylatio
## Abstract ## BACKGROUND. Excision repair cross‐complementation Group 1 (__ERCC1__) overexpression is associated with resistance to cisplatin‐based chemotherapy in patients with nonsmall‐cell lung cancer (NSCLC). A preliminary study also suggested that __ERCC1__ expression is associated with radi
## Abstract Lung cancer is one of the deadliest types of cancer proven by the poor survival and high relapse rates after surgery. Recently discovered microRNAs (miRNAs), small noncoding RNA molecules, play a crucial role in modulating gene expression networks and are directly involved in the progre